ATE259378T1 - Materialien und methoden mit bezug zur identifizierung und sequenzierung des krebs- suszeptilitaetsgens brca2 und dessen anwendungen - Google Patents

Materialien und methoden mit bezug zur identifizierung und sequenzierung des krebs- suszeptilitaetsgens brca2 und dessen anwendungen

Info

Publication number
ATE259378T1
ATE259378T1 AT96939218T AT96939218T ATE259378T1 AT E259378 T1 ATE259378 T1 AT E259378T1 AT 96939218 T AT96939218 T AT 96939218T AT 96939218 T AT96939218 T AT 96939218T AT E259378 T1 ATE259378 T1 AT E259378T1
Authority
AT
Austria
Prior art keywords
brca2
cancer
sequencing
identification
susceptileity
Prior art date
Application number
AT96939218T
Other languages
English (en)
Inventor
Phillip Andrew Futreal
Richard Francis Wooster
Alan Ashworth
Michael Rudolf Stratton
Original Assignee
Cancer Res Campaign Tech
Univ Duke
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27267991&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE259378(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9523959.6A external-priority patent/GB9523959D0/en
Priority claimed from GBGB9525555.0A external-priority patent/GB9525555D0/en
Priority claimed from GBGB9617961.9A external-priority patent/GB9617961D0/en
Application filed by Cancer Res Campaign Tech, Univ Duke filed Critical Cancer Res Campaign Tech
Application granted granted Critical
Publication of ATE259378T1 publication Critical patent/ATE259378T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
AT96939218T 1995-11-23 1996-11-25 Materialien und methoden mit bezug zur identifizierung und sequenzierung des krebs- suszeptilitaetsgens brca2 und dessen anwendungen ATE259378T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB9523959.6A GB9523959D0 (en) 1995-11-23 1995-11-23 Materials and methods relating to the diagnosis and prophylactic and therapeutic treatment of cancer
GBGB9525555.0A GB9525555D0 (en) 1995-12-14 1995-12-14 Materials and methods relating to the diagnosis and prophylactic and therapeutic treatment of cancer
GBGB9617961.9A GB9617961D0 (en) 1996-08-28 1996-08-28 Materials and methods relating to the diagnosis and prophylactic and therapeuti treatment of cancer
PCT/GB1996/002904 WO1997019110A1 (en) 1995-11-23 1996-11-25 Materials and methods relating to the identification and sequencing of the brca2 cancer susceptibility gene and uses thereof

Publications (1)

Publication Number Publication Date
ATE259378T1 true ATE259378T1 (de) 2004-02-15

Family

ID=27267991

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96939218T ATE259378T1 (de) 1995-11-23 1996-11-25 Materialien und methoden mit bezug zur identifizierung und sequenzierung des krebs- suszeptilitaetsgens brca2 und dessen anwendungen

Country Status (10)

Country Link
US (1) US6045997A (de)
EP (1) EP0858467B1 (de)
JP (1) JP2001507563A (de)
AT (1) ATE259378T1 (de)
AU (1) AU707636C (de)
CA (1) CA2238010A1 (de)
DE (1) DE69631540T2 (de)
DK (1) DK0858467T3 (de)
ES (1) ES2217328T3 (de)
WO (1) WO1997019110A1 (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5605798A (en) 1993-01-07 1997-02-25 Sequenom, Inc. DNA diagnostic based on mass spectrometry
CA2239733C (en) * 1995-12-18 2001-04-03 Myriad Genetics, Inc. Chromosome 13-linked breast cancer susceptibility gene
AU773601B2 (en) * 1995-12-18 2004-05-27 Endorecherche Inc. Chromosome 13-linked breast cancer susceptibility gene
US5837492A (en) * 1995-12-18 1998-11-17 Myriad Genetics, Inc. Chromosome 13-linked breast cancer susceptibility gene
US20030022184A1 (en) * 1996-02-12 2003-01-30 Oncormed. Inc. Coding sequences of the human BRCA1 gene
US6838256B2 (en) 1996-02-12 2005-01-04 Gene Logic Inc. Coding sequences of the human BRCA1 gene
CA2270132A1 (en) 1996-11-06 1998-05-14 Sequenom, Inc. Dna diagnostics based on mass spectrometry
CA2274587A1 (en) 1996-12-10 1998-06-18 Genetrace Systems Inc. Releasable nonvolatile mass-label molecules
WO1998041657A1 (en) * 1997-03-20 1998-09-24 Affymetrix, Inc. Iterative resequencing
US20140302494A9 (en) * 1997-08-15 2014-10-09 Myriad Genetics, Incorporated Method of analyzing a brca2 gene in a human subject
US20090269814A1 (en) * 1998-05-22 2009-10-29 Murphy Patricia D Method of Analyzing a BRCA2 Gene in a Human Subject
JP2001514887A (ja) * 1997-08-15 2001-09-18 オンコーメッド・インコーポレイテッド ヒトｂｒｃａ２遺伝子のコード配列半数型
US6207370B1 (en) 1997-09-02 2001-03-27 Sequenom, Inc. Diagnostics based on mass spectrometric detection of translated target polypeptides
US6492109B1 (en) * 1997-09-23 2002-12-10 Gene Logic, Inc. Susceptibility mutation 6495delGC of BRCA2
US6686163B2 (en) 1998-05-06 2004-02-03 Gene Logic Inc. Coding sequence haplotype of the human BRCA1 gene
US6562958B1 (en) * 1998-06-09 2003-05-13 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to Acinetobacter baumannii for diagnostics and therapeutics
US20030180789A1 (en) * 1998-12-30 2003-09-25 Dale Roderic M.K. Arrays with modified oligonucleotide and polynucleotide compositions
US6087112A (en) * 1998-12-30 2000-07-11 Oligos Etc. Inc. Arrays with modified oligonucleotide and polynucleotide compositions
US6579969B1 (en) * 1999-02-24 2003-06-17 Juan Saus Goodpasture antigen binding protein
IL143936A0 (en) 1999-10-21 2002-04-21 Univ Case Western Reserve Gene expression profiling of inflammatory bowel disease
AT409381B (de) * 2000-03-03 2002-07-25 Gloessl Josef Dr Xylosyltransferase-gen
US6727353B2 (en) * 2000-04-14 2004-04-27 Icagen, Inc. Nucleic acid encoding Kv10.1, a voltage-gated potassium channel from human brain
DE60134275D1 (de) 2000-06-15 2008-07-10 Novartis Vaccines & Diagnostic Polynukleotide zur bestimmung von kolonkrebs
AU2001278872A1 (en) 2000-07-06 2002-01-21 Genvec, Inc. Method of identifying a binding partner of a gene product
ATE396539T1 (de) 2000-07-13 2008-06-15 Ct Concept Technologie Ag Verfahren und vorrichtung zur zustandsabhängigen regelung des transienten verhaltens von leistungshalbleiterschaltern
US20030175749A1 (en) * 2001-12-08 2003-09-18 Jong-Yoon Chun Annealing control primer and its uses
WO2003104429A2 (en) * 2002-06-10 2003-12-18 Idec Pharmaceuticals Corporation Genes overexpressed by ovarian cancer and their use in developing novel therapeutics
US7461048B2 (en) * 2003-07-21 2008-12-02 Aureon Laboratories, Inc. Systems and methods for treating, diagnosing and predicting the occurrence of a medical condition
US8759089B2 (en) * 2007-02-06 2014-06-24 Geneprotech, Inc. Methods and systems for high homologous recombination (“HR”) targeting efficiency
US7892823B2 (en) * 2007-02-06 2011-02-22 Geneprotech, Inc. Methods and systems for high homologous recombination (“HR”) targeting efficiency
US20130058979A1 (en) * 2009-11-30 2013-03-07 Agency For Science, Technology And Research Treatment and prevention of cancers associated with intracellular oncoproteins by antibody therapy or vaccination
EP4012049A3 (de) 2014-04-04 2022-08-24 Crown Bioscience, Inc. (Taicang) Verfahren zur bestimmung der reaktion auf einen mek/erk-hemmer
US11773449B2 (en) 2017-09-01 2023-10-03 The Hospital For Sick Children Profiling and treatment of hypermutant cancer
CN116179710B (zh) * 2023-03-14 2023-11-24 成都诺森医学检验有限公司 基于高通量测序平台的brca1/2基因突变检测的引物组、文库构建与环化方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0393502T3 (da) * 1989-04-19 1996-03-04 Hoffmann La Roche Opløselige interferon-gamma-receptorer og fremgangsmåder til fremstilling heraf
US5464758A (en) * 1993-06-14 1995-11-07 Gossen; Manfred Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters
WO1995019369A1 (en) * 1994-01-14 1995-07-20 Vanderbilt University Method for detection and treatment of breast cancer
AU677891B2 (en) * 1994-01-14 1997-05-08 Taisho Pharmaceutical Co., Ltd. Thiazoline derivative

Also Published As

Publication number Publication date
AU707636B2 (en) 1999-07-15
DK0858467T3 (da) 2004-06-14
AU707636C (en) 2003-01-16
ES2217328T3 (es) 2004-11-01
WO1997019110A1 (en) 1997-05-29
EP0858467A1 (de) 1998-08-19
EP0858467B1 (de) 2004-02-11
US6045997A (en) 2000-04-04
JP2001507563A (ja) 2001-06-12
DE69631540T2 (de) 2005-01-27
CA2238010A1 (en) 1997-05-29
AU7635096A (en) 1997-06-11
DE69631540D1 (de) 2004-03-18

Similar Documents

Publication Publication Date Title
DE69631540D1 (de) Materialien und methoden mit bezug zur identifizierung und sequenzierung des krebs-suszeptilitaetsgens brca2 und dessen anwendungen
EP1295944A3 (de) GDP-Dissoziation stimulierendes Protein, gehirnspezifisches Nucleosomfügungsprotein, Skelettmuskel-spezifisches Ubiquitin-Conjugationsenzym, Zellproliferationsprotein, Phosphatidylinositolkinase, Nel verwandte Proteine
DK1005540T3 (da) IKK-beta-proteiner, nukleinsyrer og fremgangsmåder
ATE280226T1 (de) Genetische marker für brust und eierstockkrebs
DE69333815D1 (de) Gentranskription und ionisierende strahlung: methoden und zusammensetzungen
PT917571E (pt) Gene relacionado com agouti
EP1126034A3 (de) Kodierende Sequenzen des menschlichen BRCA1-Gens
DE69840387D1 (de) Nik proteine, nukleinsäure sowie verfahren
DE69841674D1 (de) Vermischen von heterologen dns-sequenzen
IL138330A0 (en) Polynucleotides, polypeptides and pharmaceutical compositions for treating lung cancer
ATE209684T1 (de) Dna-sequenzen für matrix-metallproteasen, ihre herstellung und verwendung
DE3650266D1 (de) DNS-Sequenzen, rekombinante DNS-Moleküle und Verfahren zur Herstellung von "mullerian inhibiting substance"-ähnlichen Polypeptiden.
NZ279963A (en) Human tissue inhibitor of metalloproteinase-4 (timp-4) and dna (rna) encoding polypeptide which may be derived from atcc 75946
EP0947583A3 (de) Expressionsaktivierende Nukleinsäurefragmente des Melanom-inhibierenden Proteins (MIA)
GR852940B (de)
EP1100815A4 (de) Von protease typ ii spaltbares peptid
WO2004076614A3 (de) Humane nukleinsäuresequenzen aus prostatakarzinomen
DE69931759D1 (de) Methode zur erstellung von genexpressionsprofilen
MX9805299A (es) Novedosos polinucleotidos panc1a y panc1b asociados con cancer pancreatico.
CY1110911T1 (el) Ανθρωπινο γονιδιο tsc403
DE69733491D1 (de) In Krebszellen überexprimiertes Genprodukt
WO2005049818A3 (en) Genes encoding human deubiquitinating enzymes
DE60222669D1 (de) Asthma-assoziiertes gen
DE60120187D1 (de) Verkürztes bard1 protein und dessen diagnostische und therapeutische anwendungen
BR0210835A (pt) Moléculas de agrecanase

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0858467

Country of ref document: EP